文献速递脑血管病

抗炎溶栓药JX10(TMS-007)用于晚就诊急性缺血性卒中

Anti-Inflammatory Thrombolytic JX10 (TMS-007) in Late Presentation of Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2024-11-07

这项多中心、随机、双盲、安慰剂对照、剂量递增2a期研究纳入90例日本急性缺血性卒中患者,在最后已知正常12小时内接受JX10或安慰剂单次静脉输注。JX10组症状性颅内出血发生率为0%(0/52),安慰剂组为2.6%(1/38),P=0.42;JX10组90天改良Rankin量表0-1分比例为40.4%(21/52),高于安慰剂组的18.4%(7/38),P=0.03。作者认为JX10耐受性良好,可能扩展急性缺血性卒中的治疗时间窗。

要点

  • JX10组症状性颅内出血发生率为0%(0/52),安慰剂组为2.6%(1/38),P=0.42。
  • JX10组90天改良Rankin量表0-1分比例为40.4%(21/52),安慰剂组为18.4%(7/38),P=0.03。
  • 基线动脉闭塞病变评分<3分的患者中,JX10组24小时血管通畅改善比例为58.3%(14/24),安慰剂组为26.7%(4/15),比值比4.23(95%CI 0.99-18.07)。

核心结论

  • JX10耐受性良好,作为新型溶栓药可能扩展急性缺血性卒中的治疗时间窗。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照、剂量递增2a期研究,纳入90例无法在最后已知正常12小时内接受组织型纤溶酶原激活剂或取栓的日本急性缺血性卒中患者。
  • 患者接受单次静脉输注安慰剂(n=38)或JX10 1、3、6 mg/kg(n=6、18、28)。

主要发现

  • 症状性颅内出血(给药后24小时内美国国立卫生研究院卒中量表评分恶化≥4分)发生率:JX10组0%(0/52,95%CI 0.0-5.6) vs 安慰剂组2.6%(1/38,95%CI 0.1-13.8),P=0.42。
  • 基线动脉闭塞病变评分<3分的患者(39/90)中,24小时血管通畅改善比例:JX10组58.3%(14/24) vs 安慰剂组26.7%(4/15),比值比4.23(95%CI 0.99-18.07)。
  • 90天改良Rankin量表评分0-1分比例:JX10组40.4%(21/52) vs 安慰剂组18.4%(7/38),P=0.03。
  • JX10组中位年龄76.5岁(范围42-87),基线中位美国国立卫生研究院卒中量表评分8分(范围6-21);安慰剂组中位年龄75.0岁(范围34-85),基线中位评分8分(范围6-22)。
  • JX10组中位给药时间(距最后已知正常)9.5小时(范围5.0-12.1),安慰剂组10.0小时(范围3.7-12.0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contemporary thrombolytics in acute ischemic stroke are limited to administration within 4.5 hours of last known normal. JX10 (formerly TMS-007), a Stachybotrys microspora triprenyl phenol family member, may extend this therapeutic window. METHODS: In this multicenter, randomized, double-blind, placebo-controlled, dose-escalation phase 2a study, JX10 or placebo was administered as a single intravenous infusion to Japanese patients with acute ischemic stroke who were unable to receive tissue-type plasminogen activator or thrombectomy within 12 hours of last known normal. Primary end point was incidence of symptomatic intracranial hemorrhage with a worsening National Institutes of Health Stroke Scale score of ≥4 points within 24 hours of drug administration (symptomatic intracranial hemorrhage incidence). RESULTS: Ninety patients received either placebo (n=38; female 26.3%) or JX10 at 1, 3, or 6 mg/kg (n=6, 18, 28; female 0%, 33.3%, and 42.9%, respectively). Median age (range) and baseline median (range) National Institutes of Health Stroke Scale scores were respectively 76.5 (42-87) and 8 (6-21) for the combined JX10 cohort (JX10 Cohorts) and 75.0 (34-85) and 8 (6-22) for placebo. Median (range) dosing time since last known normal was 9.5 (5.0-12.1) and 10.0 (3.7-12.0) hours for JX10 Cohorts and placebo, respectively. Symptomatic intracranial hemorrhage incidence was 0% (0/52 [95% CI, 0.0-5.6]) for JX10 Cohorts versus 2.6% (1/38 [95% CI, 0.1-13.8]) for placebo (P=0.42). Vessel patency at 24 hours (secondary end point) in patients with baseline arterial occlusive lesion score <3 (39/90) improved in 58.3% (14/24) of patients in JX10 Cohorts versus 26.7% (4/15) for placebo (odds ratio, 4.23 [95% CI, 0.99-18.07]). In JX10 Cohorts, a significantly higher proportion of patients had modified Rankin Scale scores of 0 to 1 on day 90 (secondary end point) versus placebo (JX10: 21/52, 40.4% versus placebo: 7/38, 18.4%; P=0.03). CONCLUSIONS: JX10 was well tolerated and may expand the acute ischemic stroke therapeutic window as a novel thrombolytic agent. REGISTRATION: URL: https://rctportal.niph.go.jp/en; Unique identifier: jRCT2080223786.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Niizuma K, Nishimura N, Hasegawa K, et al. Anti-Inflammatory Thrombolytic JX10 (TMS-007) in Late Presentation of Acute Ischemic Stroke. Stroke. 2024. PMID: 39508107. doi:10.1161/STROKEAHA.124.048464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。